Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

State Street SPDR Bloomberg High Yield Bond ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg High Yield Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.95, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals.

JNKZBH
Sector
Fixed IncomeHealth
52-Week High
$98.19$107.71
52-Week Low
$94.66$79.58
Market Cap
$17.36B
Enterprise Value
$24.40B
Dividend Yield
1.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg High Yield Bond ETF

JNK trades at $95.95, down slightly by 0.03% with a bearish technical outlook from moving averages and oscillators. The ETF shows consistent dividend payments but lacks key financial ratio data for fundamental assessment. Recent news highlights bond market volatility and investor focus on high-yield opportunities amid Federal Reserve uncertainty.

The outlook remains cautious due to technical weakness and macroeconomic pressures from potential rate hikes. Risks include fee erosion over time and sensitivity to interest rate changes, while the current yield may appeal to income-focused investors in a volatile market environment.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.

ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg High Yield Bond ETF

JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.

Read more on JNK

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH